Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

scientific article

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1155/2017/6218129
P932PMC publication ID5585574
P698PubMed publication ID28912972

P50authorHiroya TakamiQ96250575
P2093author name stringHiromichi Gotoh
Kazunori Washio
P2860cites workIncreased risk of hip fracture among Japanese hemodialysis patients.Q51282990
Bisphophonates in CKD patients with low bone mineral density.Q54313739
Effects of denosumab on fracture and bone mineral density by level of kidney functionQ58970644
A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in JapanQ64110616
Increased risk of hip fracture among patients with end-stage renal diseaseQ73969374
Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort studyQ84302487
Denosumab for low bone mass in hemodialysis patients: a noncontrolled trialQ87318313
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationQ24311588
Denosumab for prevention of fractures in postmenopausal women with osteoporosisQ28254528
A single-dose study of denosumab in patients with various degrees of renal impairmentQ36420481
Theoretical implications of the biomechanical fracture thresholdQ37197279
High rates of death and hospitalization follow bone fracture among hemodialysis patientsQ37542005
Severe hypocalcemia following denosumab injection in a hemodialysis patientQ38031326
Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literatureQ38227586
Safety and efficacy of denosumab in osteoporotic hemodialysed patientsQ39618928
Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysisQ40217335
An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysisQ42650905
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P304page(s)6218129
P577publication date2017-08-22
P1433published inInternational Journal of NephrologyQ26842036
P1476titleDenosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study
P478volume2017

Reverse relations

Q88527655Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studiescites workP2860

Search more.